Your browser doesn't support javascript.
loading
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
Hou, Mimi M; Barrett, Jordan R; Themistocleous, Yrene; Rawlinson, Thomas A; Diouf, Ababacar; Martinez, Francisco J; Nielsen, Carolyn M; Lias, Amelia M; King, Lloyd D W; Edwards, Nick J; Greenwood, Nicola M; Kingham, Lucy; Poulton, Ian D; Khozoee, Baktash; Goh, Cyndi; Hodgson, Susanne H; Mac Lochlainn, Dylan J; Salkeld, Jo; Guillotte-Blisnick, Micheline; Huon, Christèle; Mohring, Franziska; Reimer, Jenny M; Chauhan, Virander S; Mukherjee, Paushali; Biswas, Sumi; Taylor, Iona J; Lawrie, Alison M; Cho, Jee-Sun; Nugent, Fay L; Long, Carole A; Moon, Robert W; Miura, Kazutoyo; Silk, Sarah E; Chitnis, Chetan E; Minassian, Angela M; Draper, Simon J.
Afiliación
  • Hou MM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Barrett JR; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Themistocleous Y; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Rawlinson TA; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Diouf A; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Martinez FJ; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Nielsen CM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Lias AM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • King LDW; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
  • Edwards NJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
  • Greenwood NM; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Kingham L; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Poulton ID; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Khozoee B; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Goh C; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Hodgson SH; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Mac Lochlainn DJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Salkeld J; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Guillotte-Blisnick M; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Huon C; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Mohring F; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Reimer JM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Chauhan VS; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Mukherjee P; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Biswas S; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Taylor IJ; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Lawrie AM; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Cho JS; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Nugent FL; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Long CA; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Moon RW; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Miura K; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
  • Silk SE; Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
  • Chitnis CE; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
  • Minassian AM; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
  • Draper SJ; Unité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
Sci Transl Med ; 15(704): eadf1782, 2023 07 12.
Article en En | MEDLINE | ID: mdl-37437014
ABSTRACT
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% (n = 6) compared with unvaccinated controls (n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Parásitos / Malaria Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Parásitos / Malaria Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido